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Humanepidermal growth factor receptor 3 (HER3) is a
receptor tyrosine kinase that lacks catalytic activity
but is essential for cellular homeostasisdue to its abil-
ity to allosterically activateEGFRandHER2.Although
catalytically inactive, HER3 binds ATP tightly, hinting
at a possible role of the nucleotide-binding pocket in
modulating HER3 function. We report a structure of
the HER3 pseudokinase bound to the ATP-competi-
tive inhibitor bosutinib. Previously solved structures
show that bosutinib can potently interact with multi-
ple kinase domain conformations. In complex with
HER3, bosutinib binds to yet another conformation,
which is nearly identical to that observed in the
HER3-ATP complex. Interestingly, occupation of the
ATP-binding site by bosutinib improves the ability
of HER3 to act as an allosteric activator of EGFR
in vitro by increasing the affinity of the HER3-EGFR
heterodimer in a membrane-dependent manner.
INTRODUCTION
Pseudokinases represent a subgroup of the kinase superfamily,
whose members are catalytically inactive but retain an overall ki-
nase domain fold. Several pseudokinases play important roles
as allosteric regulators of other proteins (Boudeau et al., 2006).
HER3, a member of the human epidermal growth factor receptor
(HER/ErbB) family of tyrosine kinases, which also includes
EGFR, HER2, and HER4, is a pseudokinase frequently deregu-
lated in human cancers (Amin et al., 2010). HER3 is capable
of signaling through ligand-induced heterodimerization with
EGFR and HER2, which results in tyrosine phosphorylation of
the HER3 C-terminal tail and subsequent activation of the
phosphatidylinositol 3-kinase/Akt pathway. Sustained HER3
phosphorylation contributes to drug-induced resistance to
HER2-targeting agents in breast cancer and EGFR-directed
therapies in lung adenocarcinoma (Engelman et al., 2005; Ser-
gina et al., 2007). These findings identify HER3 as an important
target for anticancer therapies.
The pseudokinase domain of HER3 plays a vital role in the cat-
alytic activation of HER receptors with which HER3 dimerizesChemistry & Biology 21,upon ligand binding. This is possible because activation of
HER-family kinases requires formation of an asymmetric dimer
between two kinase domains in which one kinase (the activator
kinase) does not require catalytic activity but rather serves as
an allosteric activator of its dimerization partner (the receiver ki-
nase) (Zhang et al., 2006). In complex with other HER receptors,
HER3 assumes the role of the activator kinase, and mutation of
the HER3 activator interface, which directly contacts the receiver
kinase, ablates catalytic activation of the signaling partners of
HER3 (Jura et al., 2009b). The allosteric activator function of
the HER3 pseudokinase domain is therefore an attractive target
for HER3-directed therapies. However, selective targeting of the
HER3 activator interface with small molecule inhibitors is a chal-
lenging goal because it is relatively flat, hydrophobic, and highly
conserved among HER receptors.
Despite lacking catalytic activity, HER3 binds ATP tightly (Jura
et al., 2009b; Shi et al., 2010). Residues important for ATP coor-
dination, including the catalytic lysine (K723) and the aspartate
residue within the aspartate-phenylalanine-glycine (DFG) motif
(D833), are evolutionarily conserved in HER3. This suggests
that ATP binding might be essential for HER3 function by playing
a noncatalytic role, in a manner analogous to that previously
described for the STRADa pseudokinase (Zeqiraj et al., 2009).
As a consequence, small molecules that occupy the ATP-bind-
ing site of HER3 may regulate its ability to serve as an allosteric
activator of other HER-family kinases. Although there are
currently no reported ATP-competitive molecules developed
specifically for HER3, an unbiased screen of 72 different ATP-
competitive inhibitors against 442 human kinases identified bo-
sutinib (SKI-606) as a high-affinity binder of HER3 (Kd 0.77 nM)
(Davis et al., 2011). Bosutinib is a 4-anilinoquinoline-3-carboni-
trile inhibitor and is similar in structure to gefitinib and erlotinib,
Food and Drug Administration-approved inhibitors of EGFR
and HER2. Using bosutinib, we addressed the intriguing possi-
bility that binding of an ATP-competitive molecule to the HER3
pseudokinase domain could regulate its allosteric activator
function.
RESULTS AND DISCUSSION
We first confirmed that bosutinib does in fact bind HER3 with
high affinity. The HER3-bosutinib dissociation constant was
determined to be 0.52 ± 0.06 nM, in close agreement with the
previously reported value (Figure S1 available online) (Davis453–458, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 453
Figure 1. Crystal Structure of the HER3 Pseudokinase Domain Bound to Bosutinib
(A) Overall structural organization of the HER3-bosutinib complex, highlighting the conformation of the aC helix (blue) and the activation loop (red).
(B) Overlay of bosutinib and AMP-PNP bound in the HER3 ATP-binding site. Carbon atoms of bosutinib are shown in magenta; those of AMP-PNP are shown
in green.
(C) Close-up view of ligand interactions with selected HER3 residues involved in bosutinib and AMP-PNP binding. HER3-AMP-PNP: PDB ID code 3KEX.
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gatekeeper residue (T768I), a position that serves as a master
regulator for access of small molecules to the ATP-binding site
of kinases (Blencke et al., 2004; Noble et al., 2004). We then
determined a crystal structure of the HER3-bosutinib complex
to a resolution of 2.5 A˚ (Figure 1; Figure S2; Table S1). The struc-
ture contains the kinase domain of HER3 with bosutinib bound in
the ATP-binding cleft in a manner similar to the previously re-
ported complexes of bosutinib with the Abl and CamKII kinases
(Chao et al., 2011; Levinson and Boxer, 2012). Despite similar-
ities in the drug-binding mode, bosutinib-bound HER3 adopts
a significantly different conformation from either Abl or CamKII
in their bosutinib-bound states (Figure 2; Figure S3). In the struc-
tures of Abl and CamKII, the activation loop is in a fully extended
conformation and the catalytically critical aC helix is rotated
toward the active site, which is reminiscent of an active state
of a kinase. However, the catalytically important DFG motif is
in the inactive conformation, called DFG-out, in which the
phenylalanine replaces the aspartate in the nucleotide-binding
pocket. Bosutinib-bound HER3 adopts a very different confor-
mation. Its DFG-aspartate is oriented toward the active site
(DFG-in conformation), but the aC helix and the activation loop
adopt an inactive position denoted as the Src/CDK-like inactive
conformation. In this conformation, the aC helix is rotated away
from the active site and the N-terminal portion of the activation
loop forms a single-turn helix. The same conformation is adop-
ted by the HER3 kinase domain bound to the ATP analog
adenylyl-imidodiphosphate (AMP-PNP) (root-mean-square de-
viation 0.39 A˚) (Figure S4) (Jura et al., 2009b; Shi et al., 2010).
This is surprising given the significantly different binding modes
employed by bosutinib and the nucleotide, which show similarity
only through a partial overlay between the quinoline ring of
bosutinib and the adenine ring of the nucleotide (Figure 1B).
The methoxy substituent of bosutinib’s quinoline ring extends
in the same direction as the ribose sugar of AMP-PNP, but the
2,4-dichloro-5-methoxyaniline fragment lies 4–8 A˚ away from
the triphosphate linkage. This region of bosutinib packs deeper
into the ATP-binding cleft, where it nonetheless interacts with a454 Chemistry & Biology 21, 453–458, April 24, 2014 ª2014 Elseviersubset of HER3 residues involved in phosphate binding, in-
cluding K723 and D833 (Figure 1C). Weaker electron density
corresponding to the N-propoxy-N-methylpiperazine moiety in-
dicates that this region of bosutinib does not interact strongly
with HER3 (Figure S2B).
Binding of a small molecule to the nucleotide-binding pocket
has recently been shown to regulate the allosteric functions of
several kinases (Hatzivassiliou et al., 2010; Korennykh et al.,
2011; Okuzumi et al., 2009; Poulikakos et al., 2010). Because
such functionality would present a potential strategy to regulate
HER3, we investigated whether bosutinib can modulate the allo-
steric activator function of HER3. We reconstituted the EGFR-
HER3 heterodimer in vitro using purified HER3 and EGFR kinase
domains and small unilamellar vesicles (Jura et al., 2009b). The
EGFR kinase domain contained a V924R mutation, which pre-
vents EGFR from functioning as an activator kinase and thus re-
quires heterodimerization with HER3 for catalytic activation (Jura
et al., 2009b). The reconstituted heterodimer was incubated with
increasing concentrations of bosutinib and assayed for EGFR ki-
nase activity. At high inhibitor concentrations, both HER3 and
EGFR are bound by bosutinib, resulting in decreased catalytic
activity due to EGFR inhibition (Figures 3A and 3D). However,
at lower concentrations, where only HER3 should be bound by
bosutinib due to a 45-fold higher binding affinity of bosutinib to
HER3 than to EGFR (Davis et al., 2011), the HER3-dependent
catalytic activity of EGFR-V924R was enhanced. This suggested
that bosutinib binding might regulate the allosteric activator
function of HER3.
To separate the effect of bosutinib on the activator function of
HER3 from its direct inhibition of the EGFR kinase, we made
EGFR refractory to bosutinib binding by introducing the gate-
keeper mutation T766M (Davis et al., 2011). The basal catalytic
activity of EGFR-V924R/T766M is increased compared to that
of EGFR-V924R, but it is still highly dependent on dimerization
with HER3 (Figure 3B). In contrast to EGFR-V924R, the catalytic
activity of EGFR-V924R/T766M was enhanced at all bosutinib
concentrations (Figures 3B and 3D). To test whether this effect
is mediated by bosutinib binding to HER3, we eliminated theLtd All rights reserved
Figure 2. Comparison between HER3-Bosutinib, Abl-Bosutinib, and CamKII-Bosutinib Complexes
(A) HER3-bosutinib.
(B) Abl-bosutinib.
(C) CamKII-bosutinib.
Upper: cartoon representations highlighting the overall structural organization of the aligned kinase domains. Helix aC and the activation loop of each kinase are
shown in blue and red, respectively. Carbon atoms of bosutinib are shown in magenta. Lower: close-up views of the interactions between bosutinib and the DFG
motif of each kinase domain. Abl-bosutinib: PDB ID code 3UE4; CamKII-bosutinib: PDB ID code 3SOA.
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mutation T768I. In this context, bosutinib failed to potentiate
the kinase activity of EGFR-V924R/T766M (Figures 3C and
3D). Thus, binding of bosutinib to the ATP-binding site of HER3
enhances its function as an allosteric activator of the EGFR
kinase.
We next sought to characterize the mechanism by which
bosutinib enhances the allosteric function of HER3. A likely
explanation is that bosutinib binding increases the strength of
the association between the EGFR and HER3 kinase domains.
If this were the case, bosutinib would not be expected to in-
crease HER3 function under conditions in which all EGFR ki-
nases are bound by HER3. The interaction between isolated
kinase domains is very weak (Jura et al., 2009a; Zhang et al.,
2006), and we were unable to saturate the EGFR-HER3 hetero-
dimer on the surface of lipid vesicles due to limited binding
capacity of the lipid membrane (Figure S5). To increase the
EGFR-HER3 binding affinity, we extended the kinase domain
constructs to include the juxtamembrane segments (JM-EGFR
and JM-HER3), which potently increase HER receptor dimeriza-
tion (Jura et al., 2009a). Using these constructs, we were able to
reach near-saturating concentrations of JM-HER3 on vesicles
(Figure 4A, left plot). Under these conditions, bosutinib increased
EGFR activation only at low concentrations of JM-HER3. The
activating effect of bosutinib in this experiment was lower thanChemistry & Biology 21,that observed for isolated kinase domains, likely because of
the already-increased dimerization affinity imposed by the juxta-
membrane segments. When JM-HER3 levels approached satu-
ration, EGFR kinase activity could no longer be elevated by
bosutinib (Figure 4A, right plot). This result indicates that bosuti-
nib binding to the HER3 pseudokinase increases the affinity of
the EGFR-HER3 interaction.
Juxtamembrane segments can drive efficient dimerization of
HER-family kinases in solution (Jura et al., 2009a), allowing us
to determine whether bosutinib exerts its enhancing effect on
EGFR-HER3 affinity in the absence of membrane. Interestingly,
addition of bosutinib had minimal effect in this context (Fig-
ure 4B). This indicates that bosutinib binding to the HER3
pseudokinase domain potentiates EGFR-HER3 dimerization by
modulating interactions that only occur on the surface of a lipid
membrane. Although we do not currently understand the molec-
ular requirements for this effect, increasing evidence points to
an active contribution of the membrane surface in modulating
protein-protein interactions. For example, interaction with the
phospholipid bilayer is thought to negatively regulate the EGFR
kinase (Arkhipov et al., 2013; Endres et al., 2013). If a similar
mechanism were operative for HER3, bosutinib could increase
the pool of HER3 available for interaction with EGFR by disrupt-
ing such inhibitory interactions. Another inhibitory mechanism
thought to restrict HER3 function at the membrane involves the453–458, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 455
Figure 3. Effect of Bosutinib on the Allosteric Activator Function of HER3 In Vitro
(A–C) Concentration-dependent effect of bosutinib on measured kinase activity in the following bosutinib binding modalities: (A) HER3 and EGFR binding (HER3
and EGFR-V924R, orange squares); (B) HER3 binding only (HER3 and EGFR-V924R/T766M, purple circles); and (C) no binding (HER3-T768I and EGFR-V924R/
T766M, green triangles). The black stars on the EGFR kinase domains represent the V924Rmutation preventing EGFR self-activation through homodimerization.
(D) Normalized kinase activity in response to bosutinib titration.
Error bars in all plots represent SD of two independent measurements. **p < 0.001.
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and Eisenberg, 2000). In this scenario, the activating effect of
bosutinib could arise from its ability to weaken autoinhibitory
contacts between HER3 monomers.
Our results provide evidence for modulation of the allosteric
function of the HER3 pseudokinase through an ATP-competi-
tive inhibitor. HER3 therefore joins a diverse group of kinases,
including the active kinases IRE1, RAF, and Akt and the
pseudokinase STRADa, that can be regulated through their
interactions with ATP or ATP-competitive molecules (Kore-
nnykh et al., 2011; Okuzumi et al., 2009; Poulikakos et al.,
2010; Zeqiraj et al., 2009). Although the structural basis for
bosutinib-mediated regulation of HER3 is currently unknown,
the similarities between bosutinib-bound and AMP-PNP-bound
HER3 pseudokinase structures suggest that the bosutinib-
bound state mimics an ATP-bound state. Recently published
work (Red Brewer et al., 2013) investigating the mechanistic
basis for signaling by cancer-associated EGFR mutants shows
that these mutants are impaired in their allosteric activator
function (Littlefield and Jura, 2013). Because these mutations
activate EGFR through destabilization of the Src/CDK-like
inactive conformation (Shan et al., 2012; Zhang et al., 2006),
this suggests that the Src/CDK-like conformation might
be important for the allosteric activator function of HER recep-
tors. Consequently, bosutinib likely exerts its modest yet sig-
nificant activating effect on HER3 function in our assays
through enhanced stabilization of the Src/CDK-like inactive
conformation.
Although bosutinib binding increases HER3 function, it is
likely that ATP-competitive molecules could be designed to
similarly downregulate HER3 function through stabilization of
an activator-incompetent state. Such molecules would be of
therapeutic benefit in treating disease states in which HER3
signaling is misregulated. Our analysis of the interaction be-
tween bosutinib and the HER3 pseudokinase domain provides456 Chemistry & Biology 21, 453–458, April 24, 2014 ª2014 Elseviera fundamental proof of principle regarding the efficacy of future
investigations into ATP-competitive inhibitors of HER3 function.SIGNIFICANCE
The HER3 pseudokinase receptor exerts powerful control
over signaling cascades that mediate cell survival and,
consequently, HER3 is commonly deregulated in cancer.
Due to the defining feature of HER3 as a catalytically inactive
kinase, inhibiting HER3 function in a chemically tractable
manner has remained elusive. In this study, we present a
crystal structure of the kinase inhibitor bosutinib bound to
the HER3 pseudokinase domain. We further explore this
interaction to show that bosutinib binding modulates the
capacity of HER3 to function as an allosteric activator of
its coreceptor EGFR. To our knowledge, regulation of a
pseudokinase function via the binding of an ATP-competi-
tive small molecule has not been previously reported. These
results highlight the possible significance of ATP binding in
HER3 function. More importantly, our results provide a
platform for the rational design of HER3-directed ATP-
competitive small molecules that may effectively interfere
with aberrant HER3 signaling in cancer.EXPERIMENTAL PROCEDURES
Cloning and Protein Purification
The human HER3 kinase domain fragment, residues 674–1001 (numbering
without the 19 amino acid signal peptide), and the EGFR kinase domain, res-
idues 672–998 (numbering without the 24 amino acid signal peptide), were ex-
pressed in SF9 cells using the Bac-to-Bac expression system (Invitrogen) and
purified as previously described (Jura et al., 2009b; Zhang et al., 2006). Muta-
tions were introduced by QuikChange site-directed mutagenesis (Stratagene)
and confirmed by DNA sequencing. Constructs including juxtamembrane seg-
ments contained HER3 residues 648–1001 and EGFR residues 645–998. AllLtd All rights reserved
Figure 4. JM-EGFR Kinase Activity Mea-
sured under Titration with JM-HER3
(A) Kinase activity measured when JM-EGFR and
JM-HER3 constructs were concentrated on a
membrane surface. Left: observed reaction rates.
Right: fold enhancement in kinase activity pro-
duced by the addition of bosutinib.
(B) As in (A), for kinase activity measured in the
absence of lipid membranes. JM-HER3 concen-
trations in all panels reflect the bulk solution con-
centration. The concentration of JM-EGFR was
held constant in all experiments. Bosutinib con-
centrations were equal to the listed JM-HER3
concentration plus an additional 2 mM excess.
Error bars in all plots represent SD of two inde-
pendent measurements.
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ing purification.
Bosutinib Binding Assays
As described previously, bosutinib becomes fluorescent when it is bound to a
kinase (Levinson and Boxer, 2012). Purified HER3 kinase domain was mixed
with varying concentrations of bosutinib in 20 mM Tris (pH 8.0), 150 mM
NaCl. The fluorescence emission of HER3-bound bosutinib was monitored
at 463 nm with excitation at 280 nm. Background fluorescence of unbound
bosutinib was subtracted before analysis of binding data. The published
HER3-bosutinib Kd (0.77 nM) (Davis et al., 2011) was too strong to measure
via a conventional ligand titration binding assay at a concentration of HER3
required for sufficient fluorescent signal. Therefore, 1.1 mM ATP/Mg2+ was
included in the binding buffer in order to increase the apparent HER3-bosutinib
Kd to an accurately measurable value. We used a competitive binding model
Kdapp =Kdbosutinib 

1+
½ATP
KdATP

to convert the observed Kd (Kdapp) into a standard dissociation constant using
the published HER3-ATP Kd (1.1 mM) (Shi et al., 2010). Competitive binding
curves were fit to a standard single-site binding model in GraphPad Prism
(GraphPad Software).
Crystallography
TheHER3-bosutinib complexwas formedbydilution ofDMSO-solubilizedbosu-
tinib in crystallization buffer (10mMTris [pH 8.0], 150mMNaCl, 1mMDTT, 1mM
Tris[2-carboxyethyl]phosphine) to a final concentration of 210 mM. HER3 kinase
domain was then added to a final concentration of 6 mg/ml (160 mM). The com-
plex was crystallized in the hanging-drop format by diluting the above solution
with an equal volume of mother liquor containing 100 mM 2-(N-morpholino)
ethanesulfonic acid (pH 6.7), 10% PEG 20,000. Crystals were cryoprotected by
soaking in a solution containing mother liquor plus 30% glycerol, and then
flash-frozen in liquid nitrogen. Diffraction data were collected on beamline 8.3.1
of the Advanced Light Source at the Lawrence Berkeley National Laboratory.
Data processing was completed usingMosflm (Leslie and Powell, 2007) and
Scala (CCP4, 1994). Two data sets were merged to obtain greater complete-
ness in the high-resolution shells. The crystal structure was determined by
molecular replacement using a structure of the HER3 kinase domain bound
to AMP-PNP (Protein Data Bank [PDB] ID code 3KEX) after removal of the
ligand (Jura et al., 2009b). A positive electron density corresponding to bosu-
tinib was visible in the ATP-binding site immediately after molecular replace-
ment (Figure S2A). After two rounds of manual model building and automated
refinement using Coot (Emsley et al., 2010) and PHENIX (Adams et al., 2010),
respectively, bosutinib was built into the positive density and the structure was
refined to completion. Detailed statistics for data collection and refinement can
be found in Table S1.
In Vitro Kinase Assay
Kinase activity was measured using a continuous enzyme-coupled reaction
system as previously described (Zhang et al., 2006). The reaction buffer con-Chemistry & Biology 21,tained 20 mM Tris (pH 7.5), 10 mMMgCl2, 500 mMATP. Poly(4Glu:Tyr) peptide
(Sigma) was used as the phosphorylation substrate at a concentration of
1 mg/ml. Small unilamellar vesicles were produced by extrusion through a
membrane containing 100 nm pores (Whatman) using a mix of 90% 1,2-
dioleoyl-sn-glycero-3-phosphocholine and 10% 1,2-dioleoyl-sn-glycero-3-
([N-(5-amino-1-carboxypentyl)iminodiacetic acid]succinyl) (nickel salt) lipids
(Avanti Polar Lipids).
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